Search the Newsreel

BioNexus Advances VitaGuard™ Southeast Asia Rollout Following China Working Visit

BioNexus Gene Lab Corp. announced progress in commercializing its VitaGuard™ molecular residual disease (MRD) platform in Southeast Asia after a working visit to Tongshu Gene's facilities in China. The visit involved technical planning and meetings with Chinese hospitals where VitaGuard is already in commercial …

BioNexus Says VitaGuard Blood Tests Could Cost Under $300

BioNexus (BGLC) is progressing with the commercialization of its VitaGuard™ molecular residual disease (MRD) liquid-biopsy platform in Southeast Asia, targeting an initial rollout in select medical hubs in 2026. The company anticipates the cost per VitaGuard test to be under US$300, aiming to make …

Biontech Se Sponsored Adr (BNTXN) Q4 2022 Earnings Report - Results, Call & Slides

This article provides an in-depth report on BioNTech SE's (BNTXN) Q4 2022 earnings, highlighting that the company beat both EPS and revenue expectations. It details the actual EPS of $183.86 against a consensus of $154.43 and actual revenue of $76.15B versus expected revenue of …

Wells Fargo Reaffirms Their Buy Rating on BioNTech SE (BNTX)

Earnings To Watch: Beta Bionics Inc (BBNX) Reports Q2 2026 Result

Bionano Genomics Announces Date for Second Quarter 2026 Financial Results Conference Call and Webcast

Bionano Genomics, Inc. has announced it will host a conference call and live webcast on August 10, 2026, at 4:30 p.m. Eastern Time. The purpose of the call is to discuss the company's financial results for the second quarter of 2026 and provide updates …

Enterprise value to revenue forward of BioNTech SE Sponsored ADR – BX:22UA

This article provides a financial report indicating the enterprise value to revenue forward for BioNTech SE Sponsored ADR (BX:22UA). The report, presented by TradingView and utilizing data from ICE Data Services and FactSet, specifies a period, value, and change for this financial metric, noting …

BNGO|Bionano Genomics Inc|Price:1.075|Chg%:-0.005

This article provides a comprehensive stock analysis of Bionano Genomics Inc (BNGO) by TradingKey, detailing its financial health, valuation, earnings forecasts, price momentum, institutional confidence, and risk assessment. It highlights the company's significant growth potential, relatively stable fundamentals, and a "Buy" rating from multiple …

Bionano to Report Second Quarter 2026 Financial Results and Host a Conference Call Webcast on August 10, 2026

Bionano Genomics, Inc. (Nasdaq: BNGO) has announced that it will hold a conference call and live webcast on Monday, August 10, 2026, at 4:30 p.m. ET. The event will cover the company's financial results for the second quarter of 2026 and highlight recent corporate …

BioNexus Gene Lab Corp Revenue Breakdown – NASDAQ:BGLC

BioNexus Gene Lab Corp (NASDAQ: BGLC) revenue breakdown highlights Malaysia as the primary contributor, generating $5.83 million last year, down from $7.46 million the previous year. This information is derived from their financial statements, focusing on top segments and regional performance.

Beta Bionics, Inc. Revenue Breakdown – NASDAQ:BBNX

This article provides a detailed revenue breakdown for Beta Bionics Inc (BBNX) based on business segments for FY2025. The company's revenue streams are primarily from DME channel sales of iLet and single-use products, and PBP channel sales of single-use products and iLet. The data …

Beta Bionics Inc (BBNX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a detailed revenue breakdown for Beta Bionics Inc (BBNX) based on business segments for FY2025. The company's revenue streams are primarily from DME channel sales of iLet and single-use products, and PBP channel sales of single-use products and iLet. The data …

(BNTX) Price Dynamics and Execution-Aware Positioning

The article provides an AI-generated analysis of Biontech Se (NASDAQ: BNTX) stock, indicating weak sentiment across all time horizons and supporting a short bias. It highlights a significant 35.4:1 risk-reward short setup targeting a 10.4% downside. The analysis presents institutional trading strategies, including long, …

BioNTech Number of Employees 2026 | Employee Count & Headcount Data

BioNTech SE (BNTX) has approximately 7,840 employees worldwide as of March 2026, representing a 12.1% growth from 2023 but a 3.3% decline year-over-year in 2026. The company is actively hiring with 433 job postings in 2026, a 15.2% increase from 2025. Its workforce is …

Biontech SE (BNTX) Cash Flow

This article provides a detailed cash flow statement for Biontech SE (BNTX), covering both annual and quarterly data across operating, investing, and financing activities. It presents key financial metrics such as operating cash flow, capital expenditures, and free cash flow, along with year-over-year percentage …

Bionano Genomics Inc (BNGO) Cash Flow

This article provides a detailed quarterly and annual cash flow statement for Bionano Genomics Inc (BNGO), allowing investors to evaluate its financial health. It includes operating, investing, and financing cash flow data, with analysis of year-over-year changes and definitions of key financial metrics. The …

BioNexus Gene Lab Corp (BGLC) Cash Flow

This article provides a detailed cash flow statement for BioNexus Gene Lab Corp (BGLC), including quarterly and annual data for operating, investing, and financing activities. It also defines key cash flow terms and offers insights into BGLC's financial health, such as an operating cash …

Bionano's Q2 Results Webcast Will Stay Online for at Least 30 Days

Bionano Genomics Inc (BNGO) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides historical data on dividends and stock splits for Bionano Genomics Inc (BNGO). It indicates that BNGO has not distributed any dividends in the past five years but lists several stock split events, including a 60-to-1 merger on January 22, 2025, and …

Bionano Genomics Inc - Detailed Introduction, Company Background, Business Scope, Financial Data, and Market Performance

This article provides a detailed profile of Bionano Genomics Inc (BNGO), a company specializing in genome analysis solutions. It outlines their business scope, including optical genome mapping (OGM) and platform-agnostic software, and provides financial data points like market capitalization and revenue breakdown. The article …

Bionano Genomics Inc (BNGO) Earnings Date & Reports & Earnings News

Bionano Genomics Inc (BNGO) Shareholder Structure: Major Shareholders & Institutional Holdings

This article provides an overview of Bionano Genomics Inc (BNGO) shareholder structure, detailing major individual and institutional holdings. It lists the top shareholders by proportion, categorizes shareholders by type, and presents a historical view of institutional shareholdings and recent changes in activity.

BioNexus Gene Lab Corp (BGLC) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of BioNexus Gene Lab Corp (BGLC), including major individual and corporate holders, their proportionate ownership, and recent activity. It also provides institutional shareholding data over several quarters, showing changes in the number of institutions and shares held. Key …

BGLC|BioNexus Gene Lab Corp|Price:1.613|Chg%:-0.027

BioNexus Gene Lab Corp (BGLC) is a biotechnology company specializing in precision diagnostics and chemical solutions. While the stock has seen significant declines over various periods, its fundamentals are deemed healthy with significant growth potential, and it is considered fairly valued within the Biotechnology …

BBNX Q1 2026 Earnings: Narrower Loss Surprises but Shares Slip - Earnings Manipulation Risk

BNTX|Biontech SE|Price:89.330|Chg%:-2.730

This article provides a detailed financial overview and analyst ratings for BioNTech SE (BNTX). It highlights the company's healthy fundamentals, significant growth potential, and "Fairly Valued" status, despite a recent stock price dip and expectations for a short-term downward trend. Analysts currently rate BNTX …

Bionano Genomics, Inc. Revenue Breakdown – BMV:BNGO

Bionano Genomics, Inc. (BMV:BNGO) generated 513.94 million MXN in revenue last year. The "Consumables" segment was its top-performing segment, contributing 251.85 million MXN, though this was down from the previous year's 266.31 million MXN. Geographically, EMEA was the largest contributor, accounting for 254.34 million …

Biontech SE (BNTX) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Biontech SE (BNTX), listing its major shareholders and institutional holdings as of recent reporting periods. It provides a breakdown of shareholder types and highlights significant changes in shareholdings by various entities. The article also includes related ETF …

Beta Bionics (BBNX) Stock Fair Value Falls As Medtech Reset Tempers iLet And Mint Optimism

The fair value estimate for Beta Bionics (BBNX) has decreased from US$31.30 to US$19.80 per share, aligning more closely with current analyst price targets. This adjustment reflects a balance between continued optimism for their iLet product and planned Mint launch, and broader medtech sector …

Beta Bionics Inc (BBNX) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides details on Beta Bionics Inc (BBNX) stock, focusing on its dividend and stock split history. It indicates that the company has distributed $0.00 in dividends over the past five years, with no dividend data currently available. The page also presents current …

BBNX Q1 2026 Earnings: Narrower Loss Surprises, Shares Dip - Net Profit Margin

BioNexus Gene Lab Corp (BGLC) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of BioNexus Gene Lab Corp (BGLC), noting its current valuation score of 8.43, which ranks it 138 out of 386 in the Biotechnology & Medical Research industry. It highlights the company's P/E ratio of -1.02, while also stating …

Beta Bionics Inc (BBNX) Institutional Confidence

Beta Bionics Inc (BBNX) has an institutional shareholding score of 10.00, ranking it 1st in the Healthcare Equipment & Supplies industry. Institutional shareholding proportion increased by 4.12% quarter-over-quarter to 110.51%. Frank Sands is the largest institutional shareholder, holding 3.08 million shares, representing 8.01% of …

BioNTech SE Revenue Breakdown – NASDAQ:BNTX

BioNTech SE (NASDAQ: BNTX) reported a total revenue of $3.37 billion USD last year. The majority of this revenue, $3.24 billion USD, came from its Immunotherapy Technologies segment, an increase from $2.98 billion USD in the previous year. The United States was the largest …

Beta Bionics (BBNX) sees 6.9% stake reported by Divisadero Street group

A Schedule 13G SEC filing reveals that Divisadero Street Capital Management, LP, along with William Zolezzi and related entities, has acquired a significant beneficial ownership of 3,072,985 shares in Beta Bionics, Inc. (BBNX), representing 6.9% of the common stock. This filing indicates shared voting …

BGLC|BioNexus Gene Lab Corp|Price:1.510|Chg%:-0.050

BioNexus Gene Lab Corp (BGLC) is a biotechnology company specializing in precision diagnostics and chemical solutions. While the stock has seen significant declines over various periods, its fundamentals are deemed healthy with significant growth potential, and it is considered fairly valued within the Biotechnology …